News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

Al's Comment:

 This talks about the relationship between pseudoprogression and MGMT status. We already knew that MGMT methylation status is very important in determining the prognosis.. and we already knew (from our last news blast) that people with pseudoprogression do better than people without. This ties it together and may be why: those positive MGMT patients - who would be expected to live longer), also are more likely to get pseudoprogresion.. This may mean the temodar works better as a radiation sensitizer when MGMT is methylated. 


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://jco.ascopubs.org/content/26/13/2192.full


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740